KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Intangibles (2019 - 2021)

Royalty Pharma (RPRX) has disclosed Intangibles for 3 consecutive years, with $5.7 million as the latest value for Q4 2021.

  • Quarterly Intangibles fell 80.22% to $5.7 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $5.7 million through Dec 2021, down 80.22% year-over-year, with the annual reading at $5.7 million for FY2021, 80.22% down from the prior year.
  • Intangibles hit $5.7 million in Q4 2021 for Royalty Pharma, down from $11.5 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $51.7 million in Q4 2019 to a low of $5.7 million in Q4 2021.
  • Historically, Intangibles has averaged $26.6 million across 3 years, with a median of $25.8 million in 2020.
  • Biggest five-year swings in Intangibles: crashed 44.58% in 2020 and later tumbled 80.22% in 2021.
  • Year by year, Intangibles stood at $51.7 million in 2019, then plummeted by 44.58% to $28.7 million in 2020, then crashed by 80.22% to $5.7 million in 2021.
  • Business Quant data shows Intangibles for RPRX at $5.7 million in Q4 2021, $11.5 million in Q3 2021, and $17.3 million in Q2 2021.